New Australian site opening for DEP® trials
Jul 9th, 2020
Starpharma today announced the opening of a new trial site for the phase 2 DEP® irinotecan trial, at the Kinghorn Cancer Centre in Sydney. The DEP® irinotecan trial is also being conducted at multiple leading UK cancer centres including The Christie, The Royal Marsden, Newcastle Freeman Hospital, and The Beatson West of Scotland Cancer Centre. The Kinghorn Cancer Centre will also be opened shortly as an additional site for the phase 2 DEP® cabazitaxel trial.
Read More
Pandemic a catalyst for boosting commercial outcomes, says Starpharma CEO
Jul 3rd, 2020
The Age recently interviewed Starpharma CEO Dr Jackie Fairley to discuss how the COVID19 pandemic could be the catalyst for the pharmaceutical industry to improve the way they convert important research into commercial products. The article highlighted Starpharma’s recent activities in response to the pandemic, including the development of a product using its existing anti-viral dendrimer SPL7013.
To read the full article, click here.
Read More
DEP irinotecan boosts immuno-oncology in colon cancer models
Jun 29th, 2020
Starpharma today announced its SN-38 nanoparticle, DEP® irinotecan in combination with an immuno-oncology (IO) agent (anti PD-1 antibody) showed superior anti-tumour activity and significant survival benefit in two colorectal cancer (CRC) models when compared to the anti PD-1 antibody alone. These results included improvement in both survival and efficacy in the particularly aggressive CT-26 CRC model.
Read More
Starpharma CEO Dr Jackie Fairley on the ABC’s 7.30 report
Jun 25th, 2020
Alan Kohler recently interviewed Starpharma CEO Dr Jackie Fairley on the ABC’s 7.30 report to discuss the importance of developing other methods of protection against COVID-19 while we wait for a vaccine. Jackie also discusses how Starpharma’s patented dendrimer SPL7013 is being developed for use in an antiviral nasal spray to prevent COVID-19 infection.
Watch the full interview here: https://www.abc.net.au/7.30/how-long-will-the-economy-take-to-recover/12394342
Read More
Multiple DEP® products showcased at AACR 2020
Jun 23rd, 2020
Starpharma today announced that five posters featuring products based on Starpharma’s DEP® platform have been presented at the AACR (American Association for Cancer Research) Annual Meeting. The AACR Annual Meeting brings together leading cancer research and medicine from institutions all over the world and is an important forum for both raising product awareness and commercial interactions.
Read More
SBS speaks to Starpharma CEO Dr Jackie Fairley on female representation in business
Jun 19th, 2020
A new study using Australian data showed a causal link between female leadership and business performance. Starpharma is one of only 15 ASX300 companies to have a female CEO and Dr Jackie Fairley spoke with SBS about the importance of having senior female leaders in a corporate setting.
For the full interview click here.
Read More
Ausbiz interviews Starpharma CEO Dr Jackie Fairley
Jun 19th, 2020
Finance and market news website AusBiz interviewed Starpharma CEO Dr Jackie Fairley to discuss the company’s first radiotherapeutic candidate, DEP® lutetium. The candidate showed highly statistically significant anticancer activity, tumour regression and 100% survival in a human prostate cancer model. The interview also covered the company’s latest VivaGel® BV launch in Central and Eastern Europe.
To watch the full interview click here.
Read More
Starpharma to present at OTCQX Virtual Investor Conference
Jun 18th, 2020
Starpharma today announced that a pre-recorded presentation by Dr Jackie Fairley, CEO, will be broadcast on Thursday 18 June 2020 (US ET) as part of OTCQX’s Virtual Investor Conference for Global Mid-cap and Large-cap Companies. The conference is primarily attended by US-based retail investors, as well as advisors.
Read More
DEP® lutetium effective in human prostate cancer model
Jun 17th, 2020
Starpharma today announced results from its first radiotherapeutic candidate, DEP® lutetium. DEP® lutetium is a patented nanoparticle which incorporates the radioisotope Lutetium-177 on a DEP® dendrimer scaffold.
Read More
VivaGel® BV launched in central and eastern European countries
Jun 16th, 2020
Starpharma today announced that VivaGel® BV has been launched in Central and Eastern European (CEE) region. This launch follows European launches in Germany, UK and several other European countries.
Read More
Starpharma CEO Dr Jackie Fairley on Proactive Investors (Canada)
May 18th, 2020
The Canadian arm of finance news network Proactive Investors recently interviewed Starpharma CEO Dr Jackie Fairley to discuss the Company's DEP® portfolio and the recent news that Starpharma is investigating product concepts for proprietary dendrimer SPL7013 in relation to COVID-19.
Watch the full interview here: https://www.youtube.com/watch?v=jqn06bUymDw&feature=youtu.be
Read More
Shareholder Update May 2020
May 14th, 2020
In this issue:
>> VivaGel® BV launched in Asia
>> Fleurstat BVgel launched in NZ
>> DEP® irinotecan phase 2 commences after positive phase 1 results
>> SPL7013 against SARS-COV-2 (coronavirus)
>> Fleurstat BVgel ranks as #1 topical BV treatment
>> Okamoto adds 11 more Asian countries to licence
>> US regulatory update
>> COVID-19: Starpharma’s operations continue with minimal disruption
>> DEP® docetaxel, DEP® cabazitaxel and DEP® irinotecan
>> DEP® patient case studies
>> AstraZeneca’s DEP® trial ongoing in the US & US$3 million milestone payment received
>> New DEP® ADC programs
>> DEP® pipeline targets multiple high-value areas
>> Other DEP® programs
>> Outlook, recent news & events
Read More
Starpharma CEO Dr Jackie Fairley on ausbiz
May 11th, 2020
Finance and market news website AusBiz co-founders Kylie Merritt and David Koch interviewed Starpharma CEO Dr Jackie Fairley to discuss DEP® irinotecan moving into Phase 2 and how Starpharma is investigating product concepts for SPL7013 in the fight against COVID-19.
To watch the full interview click here
Read More
DEP® irinotecan phase 2 commences after positive phase 1 results
May 7th, 2020
Starpharma today announced successful completion of the phase 1 component of its phase 1 / 2 trial for DEP® irinotecan. The trial met its objective of evaluating safety, tolerability, pharmacokinetics and preliminary efficacy data, and identifying a recommended phase 2 dose. The trial will now transition seamlessly into phase 2, with recruitment activities underway at three sites. Two additional sites, The Beatson West of Scotland Cancer Centre (the Beatson) and the Kinghorn Cancer Centre in Sydney are also expected to commence recruitment shortly.
Read More
Starpharma presents at Macquarie Australia Conference
May 5th, 2020
Starpharma has been invited to present today at the Macquarie Australia Conference. Due to COVID-19, the Macquarie Australia Conference will be a virtual conference for registered institutional investors. The event will provide international and domestic institutions with the opportunity to hear from a range of invited Australian companies over three days. Starpharma is one of a handful of companies in the pharmaceutical/biotech and healthcare industries to be presenting during the conference.
Read More
Australia’s biotech sector tests multiple agents to fight COVID-19
Apr 22nd, 2020
US biotech publication BioWorld noted that a number of Australian biotech companies have been testing agents in the fight against COVID-19, in particular highlighting Starpharma’s SPL7013 which showed significant positive antiviral activity against the SARS-CoV-2 virus.
To read the full article, click here
Read More
Condom gel compound proves effective against COVID-19
Apr 16th, 2020
The Australian Financial Review interviewed Starpharma CEO Dr Jackie Fairley for an article highlighting the company’s finding that its antiviral dendrimer SPL7013 showed significant activity against coronavirus. The article noted SPL7013 is already used in existing and approved products within Starpharma’s VivaGel® portfolio.
To read the full article, click here (paywall).
Read More
Starpharma Reports Positive Results From SARS-CoV-2 Antiviral Testing Of SPL7013
Apr 16th, 2020
NASDAQ covered the news that Starpharma’s VivaGel® active, astodrimer sodium (SPL7013), showed significant antiviral activity against the coronavirus that causes COVID-19. The piece noted the testing was conducted by an external laboratory, 360Biolabs.
To read the full article, click here.
Read More
Starpharma’s SPL7013 Shows Significant Activity Against SARS-CoV-2 (coronavirus)
Apr 16th, 2020
Leading biotech industry portal BioSpace covered Starpharma’s finding that its proprietary dendrimer SPL7013 showed significant activity against SARS-CoV-2, the coronavirus that causes COVID-19. It noted Starpharma will evaluate product concepts and formulation options for SPL7013 which may have potential applications in the prevention and management of COVID-19.
To read the full article, click here
Read More
SPL7013 shows significant activity against SARS-CoV-2 (coronavirus)
Apr 15th, 2020
Starpharma today announced that its proprietary VivaGel® active, astodrimer sodium (SPL7013), has been shown in laboratory studies to have significant antiviral activity against the coronavirus that causes COVID-19 (coronavirus disease). SPL7013 inhibited the infection of cells with the SARS-CoV-2 virus and the finding was validated by replicate testing against a positive control compound, remdesivir (Gilead), which is considered a leading candidate for the treatment of COVID-19. The finding was also significant given that SPL7013 was reported to be the best performing test compound against SARS-CoV-2 in the laboratory’s assay to date. With these positive results, Starpharma is evaluating product concepts and formulation options for SPL7013, which may have potential applications in the prevention and management of COVID-19.
Read More
Quarterly Cashflow and Activity Report
Apr 7th, 2020
Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 31 March 2020.
Starpharma’s cash balance as at 31 March 2020 was $36.1 million, an increase of $0.2 million compared to the previous quarter’s cash balance. Net operating cash outflows for the quarter were $0.9 million, or $6.0 million for the nine months to 31 March 2020. Starpharma’s strong cash reserves and clean balance sheet places the Company in a strong position to continue to progress its commercial and R&D activities in the current uncertain global environment of the COVID-19 pandemic.
Read More
COVID-19 measures
Mar 30th, 2020
Starpharma continues to closely monitor the COVID-19 pandemic and its impact.
Okamoto licenses VivaGel® antiviral condom in Asian countries
Mar 4th, 2020
Starpharma today announced that following the successful launch of the VivaGel® antiviral condom by Okamoto Industries, Inc. (TYO: 5122:JP; Okamoto) in Japan, Okamoto has sought an expansion to its licence territory for the VivaGel® condom. As a result, Starpharma has granted Okamoto marketing rights to a further 11 countries in Asia which include South Korea, Indonesia, Malaysia, Thailand, Singapore and the non-government China market.
Read More
Starpharma appoints David McIntyre and Appendix 3X
Mar 2nd, 2020
Starpharma today announced that Mr David McIntyre has commenced as an independent non-executive director of Starpharma, effective 1 March. Mr McIntyre’s appointment follows a comprehensive Board renewal and search process. As advised at the Company’s last AGM, Mr Richard Hazleton will be retiring at the 2020 AGM in November, having served 13 years on the Company’s Board. The timing of Mr McIntyre’s appointment enables a smooth transition and handover between directors.
Read More
Interim Report and Half-Year Financial Results
Feb 24th, 2020
Starpharma today released its interim report and financial results for the half-year ended 31 December 2019.
Read More
Starpharma collects milestone payment from AstraZeneca
Feb 13th, 2020
Biotech Dispatch reported that AstraZeneca has paid Starpharma a $4.5 million milestone payment following the successful dosing of the first patient in the phase 1 clinical trial of AZD0466. The article mentioned the long standing partnership between the two companies which is focused on using Starpharma’s DEP® drug delivery platform to enhance AstraZeneca’s medicines.
To read the full article click here
Read More
Starpharma share price charges higher on product launch news
Feb 13th, 2020
The Motley Fool reported a rise in Starpharma’s share price off the back of the announcement that its VivaGel® BV product will be launched in Asia by Mundipharma. The article highlighted that the deal is an important commercial opportunity for Starpharma with the product set to be accessible to more than 1.5 billion women.
To read the full article, click here
Read More
VivaGel BV launched in Asia
Feb 13th, 2020
Starpharma today announced that VivaGel® BV has been launched in Asia under the brand name BETADINETM BV Gel. The product has initially been launched in South East Asia, with further roll-out in additional Asian countries, as regulatory approvals are granted.
BETADINETM BV Gel will be available over-the-counter (OTC), without the need to see a doctor or obtain a prescription. Asia is the third region to launch VivaGel® BV and represents a large commercial opportunity with access to more than 1.5 billion women.
Read More
David McIntyre appointed as non-executive director
Feb 12th, 2020
The Board of Starpharma is pleased to announce the appointment of Mr David McIntyre as an independent non-executive director, effective 1 March 2020.
Read More
Starpharma receives US$3M milestone from AstraZeneca
Feb 11th, 2020
Starpharma today announced it has received US$3 million (A$4.5 million) from AstraZeneca following the successful dosing of the first patient in the phase 1 clinical trial of AZD0466 (DEP® Bcl2/xL conjugate) in December.
Read More
Shareholder Update January 2020
Jan 30th, 2020
In this issue:
>> VivaGel® BV launched in the UK
>> AstraZeneca first DEP® product enters the clinic; triggers US$3M milestone
>> DEP® cabazitaxel trial moves into phase 2 on positive results
>> Fleurstat BVgel marketing campaign; New Zealand launch planned
>> Dual strategy to achieve approval of the NDA in the US
>> Okamoto joins forces with Japanese government for STI prevention campaign
>> VivaGel® condom receives regulatory approval in Europe
>> DEP® docetaxel & DEP® cabazitaxel clinical trial case studies
>> DEP® irinotecan phase 1/2 trial
>> New candidate - DEP® gemcitabine
>> GMP DEP® facility licence
>> DEP® combinations add further value
>> Outlook, recent news & events
Read More
Quarterly Cashflow Report
Jan 29th, 2020
Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 31 December 2019.
Read More
Commencement of phase 1 trial for AZD0466 utilising DEP®
Dec 30th, 2019
Starpharma today announced that AstraZeneca (LSE/STO/NYSE: AZN) has commenced a phase 1 clinical trial of AZD0466 (DEP® Bcl2/xL conjugate) and the first patient has been successfully dosed. The trial will recruit patients with a range of cancers and will be conducted at 4-5 US sites.
Read More
Starpharma receives $4.9M R&D tax incentive refund
Dec 16th, 2019
Starpharma today announced that it has received a $4.9M R&D tax incentive refund which relates to the costs of research and development during the 2019 Financial Year. The refund is in respect of eligible R&D activities across Starpharma’s portfolio, including DEP® and VivaGel®.
Read More
DEP® cabazitaxel progresses to phase 2 on positive results
Dec 10th, 2019
Starpharma today announced successful completion of the phase 1 component of its phase 1 / 2 trial for DEP® cabazitaxel. The trial met its objective of evaluating safety, tolerability and preliminary efficacy data, and identifying a recommended phase 2 dose of 20 mg/m2. The trial will now transition seamlessly into phase 2, with two new sites initiated and recruitment activities already underway.
Read More
AGM Chairman’s address and CEO’s presentation
Nov 21st, 2019
Melbourne, Australia: Attached is the Chairman’s address together with the CEO’s presentation to the Annual General Meeting of Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY), to be held at 4.00pm today.
Read More
VivaGel® condom receives regulatory approval in Europe
Nov 20th, 2019
Starpharma today announced that it has been granted marketing approval for the VivaGel® condom in Europe.
Read More
2019 AGM details
Nov 19th, 2019
Starpharma today notifies that its 2019 AGM will be held at 4pm on 21 November 2019 at RACV City Club, Level 2, 501 Bourke Street, Melbourne, Victoria.
The AGM will be recorded and available via webcast later that day. To access the webcast, participants can register via the following link:
https://webcasting.boardroom.media/broadcast/5dccc1f06242591605116cb6
Read More
UK launch of VivaGel® BV
Nov 13th, 2019
Starpharma today announced that VivaGel® BV has been launched in the UK under the brand Betafem® BV Gel. This launch follows the first European launches in June 2019, including in Germany and other countries.
Read More
Starpharma tech ready to deliver
Nov 11th, 2019
The Austraian published an interview with Starpharma CEO Dr Jackie Fairley where she discussed the potential of the dendrimer technology, how it is applied to cancer drugs and the potential benefits it provides to patients.
To read the full article, click here. (paywall)
Read More
Dendrimer drug delivery enhances chemotherapy gemcitabine in human pancreatic mode
Nov 1st, 2019
Online pharmaceutical publication Pharma in Focus noted Starpharma’s positive DEP® gemcitabine results in a human pancreatic model, noting it was one of multiple DEP® drugs from the company.
To read the full article, click here.
Read More
DEP® gemcitabine outperforms Gemzar® in human pancreatic cancer model
Oct 31st, 2019
Starpharma today announced results for its next internal development candidate, DEP® gemcitabine.
Read More
Quarterly Cashflow Report
Oct 30th, 2019
Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 30 September 2019.
Starpharma’s cash balance as at 30 September 2019 was $36.8 million, with net operating cash outflows for the quarter of $4.6 million. The cash balance does not include the anticipated $4.9 million R&D tax incentive which is expected to be received during the December quarter.
Read More
Starpharma to present at US Drug Delivery Conference
Oct 8th, 2019
Starpharma today announced that it has been invited once more to present at the 9th Annual Partnership Opportunities in Drug Delivery (PODD) conference in Boston, USA, on 7-8 October.
The PODD conference showcases the latest advances in drug delivery and provides networking opportunities with senior scientific and commercial executives from many of the major international pharmaceutical companies. This year’s PODD conference will be chaired by AstraZeneca’s Head of Drug Delivery, Dr Shawn Davis.
Read More
Small cap healthcare stocks surge to billion-dollar plays
Sep 30th, 2019
The Australian Financial Review mentioned that Starpharma was in a group of small cap biotech stocks in stage two trials that investors are closely in the next few years.
To read the full article, click here (paywall)
Read More
FDA Authorisation of First-in-Human Clinical Trial with AstraZeneca’s DEP® product AZD0466
Sep 26th, 2019
Starpharma today announced that that the U.S. Food and Drug Administration (FDA) has authorised the use of AstraZeneca’s DEP® Bcl2/xL conjugate AZD0466 in clinical trials under an investigational new drug (IND) application. This is the first DEP® candidate to reach this milestone from Starpharma’s multiproduct license with AstraZeneca.
Read More
DEP® irinotecan synergistic with Lynparza® in refractory human colon cancer model
Sep 12th, 2019
Starpharma today announced that its patented clinical stage nanoparticle formulation, DEP® irinotecan, showed significantly enhanced efficacy benefits over standard irinotecan (Camptosar®) and olaparib (Lynparza®) alone and in combination, in an irinotecan-refractory HT-29 human colon cancer xenograft model.
Read More
Starpharma’s VivaGel® BV regulatory approvals continue in Asia
Sep 3rd, 2019
|
Finance News Network reported Starpharma received further regulatory approval in another Asian country for its breakthrough product for bacterial vaginosis, VivaGel® BV. The news follows the first approval in the region announced on 15 August. |
Read the full news coverage here.
Read More
VivaGel® BV regulatory approvals continue in Asia
Sep 3rd, 2019
Starpharma today announced that it has received a further regulatory approval in an Asian country for VivaGel® BV. This approval follows multiple country approvals in the region as previously announced on 15 August 2019. Mundipharma will be rolling-out the product in Asia under the brand name BETADINETM BV Gel.
Read More
Update on Starpharma’s latest positive interim DEP® trial results, VivaGel® and upcoming milestones
Aug 30th, 2019
|
Online news outlet Boardroom Media interviewed Starpharma CEO Dr Jackie Fairley following the release of its annual report and full-year results. In the interview, Dr Fairley shared the company’s latest DEP® trial results, as well as VivaGel® and upcoming milestones. |
To listen to the full interview, click here.
Read More